### DOCUMENT NUMBER: PBMT-GEN-030

### DOCUMENT TITLE:
Administration of Infliximab

### DOCUMENT NOTES:

#### Document Information

- **Revision:** 07
- **Vault:** PBMT-General-rel
- **Status:** Release
- **Document Type:** General

#### Date Information

- **Creation Date:** 25 Oct 2018
- **Release Date:** 01 Dec 2018
- **Effective Date:** 01 Dec 2018
- **Expiration Date:**

#### Control Information

- **Author:** MOORE171
- **Owner:** MOORE171
- **Previous Number:** PBMT-GEN-030 Rev 06
- **Change Number:** PBMT-CCR-203
PBMT-GEN-030
ADMINISTRATION OF INFliximab

1 PURPOSE
1.1 To outline the procedure required for indications for and administration of infliximab. Responsibilities of the nursing staff for administration and monitoring reactions to infliximab are described.

2 INTRODUCTION
2.1 Infliximab is a monoclonal antibody used for the treatment of autoimmune diseases, pulmonary hemorrhage, and graft versus host disease (GVHD). It is the first marketed drug in the United States that specifically inhibits the activity of tumor necrosis factor-alpha (TNFalpha).

3 SCOPE AND RESPONSIBILITIES
3.1 Interdisciplinary: Requires a physician or designee order to be placed into the electronic medical record.
3.2 Registered Nurses (RNs) may administer infliximab after successful completion of medication administration test and demonstration of clinical competency with their preceptor.

4 DEFINITIONS/ACRONYMS
4.1 GVHD Graft Versus Host Disease
4.2 PFO Patent Foramen Ovale
4.3 RN Registered Nurse

5 MATERIALS
5.1 Medication administration line
5.2 Volumetric or syringe pump

6 EQUIPMENT
6.1 Primed primary administration set
6.2 Infliximab prepared by pharmacy for infusion
6.3 Alcohol prep
6.4 Gloves (non-sterile)
6.5 Secondary tubing if Infliximab arrives in a bag
7  SAFETY
7.1  N/A

8  PROCEDURE
8.1  Patient Assessment
   8.1.1  Assess intravenous access device for leakage, patency, and blood return.
   8.1.2  Assess central venous access site for redness, swelling, drainage and pain.
   8.1.3  Acute infusion-related reactions occur during or within 1-2 hours of administration. The most common reactions consist of nonspecific symptoms such as fever, pain, dyspnea, hypotension, and hypertension.
   8.1.4  Observe patient for adverse reactions that include:
          8.1.4.1  Anaphylaxis
          8.1.4.2  Arthralgia
          8.1.4.3  Chills
          8.1.4.4  Dyspnea
          8.1.4.5  Hypertension
          8.1.4.6  Hypotension
          8.1.4.7  Nausea and vomiting
          8.1.4.8  Diarrhea
          8.1.4.9  Abdominal pain
          8.1.4.10  Dyspepsia
   8.1.5  Have emergency medications available at bedside.
   8.1.6  Assess if patient requires Patent Foramen Ovale (PFO) filters.
   8.1.7  Assess Vital Signs pre-infusion, 15 minutes into infusion, 1 hour into the infusion and at the completion of the infusion.

8.2  Dosing and Administration:
   8.2.1  Assess IV for patency.
   8.2.2  If visibly opaque particles, discoloration, or other abnormalities are observed, the solution should not be used.
   8.2.3  The infusion should begin within 3 hours of preparation.
   8.2.4  The maximum concentration = 4 mg/mL diluted in normal saline.
   8.2.5  Infliximab prepared by pharmacy in a bag should be spiked with secondary tubing and primed then attached to primary IV set after port is cleaned with an alcohol prep.
8.2.6 Infliximab prepared by pharmacy in a syringe should be attached to primary syringe pump tubing.

8.2.7 Infuse per physician or designee orders.

8.2.7.1 The usual GVHD dose = 10 mg/kg given every week x 4 doses.

8.2.7.1.1 In patients with severe GVHD it may be given more frequently or for an extended period of time.

8.2.7.1.2 Some patients may require pre-medications for subsequent doses if infusion related reaction occurs with first dose.

8.2.7.2 Infliximab is usually administered intravenously over a minimum of 2 hours unless otherwise specified in the medication order.

8.2.8 Once complete, flush the entire line with primary solution to ensure entire medication has been infused.

9 RELATED DOCUMENTS/FORMS

9.1 NA

10 REFERENCES

10.1 2003 Thompson Micromedex Role of Tumor Necrosis Factor-Alpha in Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses.


10.3 Clinical Pharmacology, current edition.

11 REVISION HISTORY

<table>
<thead>
<tr>
<th>Revision No.</th>
<th>Author</th>
<th>Description of Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07</td>
<td>S. McCollum</td>
<td>Title updated to &quot;PBMT-GEN-030 Administration of Infliximab (formerly &quot;Infliximab (Remicade&quot;) to be in alignment with other medication infusion SOPs. Acronyms defined throughout. Steps reordered to be in order of nursing workflow under dosing and administration section. Section 8.1.7 added: Assess Vital Signs pre-infusion, 15 minutes into infusion, 1 hour into the infusion and at the completion of the infusion.</td>
</tr>
</tbody>
</table>
**PBMT-GEN-030 Administration of Infliximab**

### Author

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sally McCollum (MOORE171)</td>
<td></td>
<td>19 Nov 2018, 10:48:54 AM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

### Medical Director

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Kurtzberg (KURTZ001)</td>
<td></td>
<td>19 Nov 2018, 11:48:45 AM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

### Quality

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bing Shen (BS76)</td>
<td></td>
<td>19 Nov 2018, 04:46:29 PM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

### Document Release

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betsy Jordan (BJ42)</td>
<td></td>
<td>20 Nov 2018, 08:59:31 AM</td>
<td>Approved</td>
</tr>
</tbody>
</table>